NCT04398420终止不适用
Safety and Efficacy of TVERP in BPH Patients With Prostate Size ˃30 and ≤80 ml: a Comparison Study Between TVERP With the Plasma Vaporisation Button, Bipolar TURis and HoLEP Treatments.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 29
- 试验地点
- 3
- 主要终点
- change of blood level
研究概览
简要总结
To verify the safety and efficacy of the use of the plasma vaporisation button in Transurethral Vapor Enucleation and Resection of the prostate (TVERP) for treatment of Benign prostatic hypertrophy (BPH) patients with prostate ˃30 and ≤80 ml compare to TURis or HoLEP surgery methods.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male, age older than 22 and younger than 75 years of age
- •The patient should be a candidate for surgical treatment of bladder outlet obstruction.
- •Patients with BPH and surgical indication (refractory to medical treatment, refractory or recurrent urinary retention, recurrent haematuria, bladder stones, recurrent infections, hydronephrosis)
- •Prostate volume ˃30 and ≤80 ml
- •PSA <4 ng/ml in patients above 55 years old and a prostate cancer risk less than 35%. (Prostate cancer risk calculator).
- •IPSS ≥8 (moderate to severe)
- •Indications for TURIS
- •maximum urinary flow (Qmax) <10ml/second
- •A written informed consent signed by the patient (including patient's agreement to randomization and treatment).
排除标准
- •Patients under anti-inflammatory or steroid therapy
- •Patients under anti-coagulation at a level that could be exposed to a very high risk of complications based on a comprehensive pre-operatory evaluation.
- •Renal insufficiency Serum creatinine (Scr) >1.5 x upper limit of normal (ULN); AST and ALT>2.5 x ULN;Total bilirubin >1.5 x ULN
- •Previous neurogenic lower urinary tract dysfunction.
- •Patients with urethral strictures
- •Severe pulmonary disease and cardio-vascular disorder 、Coagulopathy，and contraindications to anesthesia and surgery.
- •Concurrent participation in any other clinical study
- •Any of the following within the 12 months prior to study: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism.
- •Previous bladder outlet surgery.
- •A clinically significant acute illness.
- •Intake of medication in which the principle investigator considers to preclude enrollment into the trial.
- •Known disease of the central or peripheral nervous system.
- •Any clinical evidence of carcinoma of the prostate.
- •HIV positive or any other immunosuppressive disorder.
- •Psychological/psychiatric disease /Known cognitive disorder.
结局指标
主要结局
change of blood level
时间窗: Measurement of pre-operative and immediate post-operative period (6 hours and 24 hours) hemoglobin and hematocrit levels will be performed.
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Pulsta® Transcatheter Pulmonary Valve Korean Multicenter StudyPulmonary Valve StenosisCongenital Heart DefectPulmonary Valve Insufficiency, CongenitalNCT03110861Taewoong Medical Co., Ltd.15
终止
不适用
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization ElectrodeBenign Prostatic HyperplasiaNCT02019030Olympus Corporation of the Americas5
进行中（未招募）
不适用
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility StudySymptomatic Aortic StenosisSevere Aortic Valve StenosisAortic Valve CalcificationAortic StenosisNCT05712161Anteris Technologies Ltd.15
Unknown
3 期
Efficacy and Safety of Venus P-valve to Treat RVOT Stenosis With Pulmonary RegurgitationRight Ventricular Outflow Tract StenosisNCT02071654Venus MedTech (HangZhou) Inc.44
招募中
不适用
Vivifi's Treatment, BPH Treatment Via Vasculature AnastomosisVaricocele Grade IIVaricocele Grade IIIBenign Prostatic HyperplasiaNCT06424912Vivifi Medical20